Published in Br J Cancer on September 11, 2014
Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | NCT01968109
Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors | NCT01629758
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | NCT01307267
PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine | NCT01441765
Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma | NCT01952769
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol (2016) 2.09
Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci Transl Med (2015) 1.42
Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer (2016) 1.08
Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses. Mol Ther (2015) 1.06
Inhibitory Receptors Beyond T Cell Exhaustion. Front Immunol (2015) 1.05
OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. Front Oncol (2015) 1.01
A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy. Comput Struct Biotechnol J (2015) 1.00
Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches. Stem Cells (2015) 0.97
Immune biomarkers: the promises and pitfalls of personalized medicine. Nat Rev Immunol (2015) 0.88
Directly targeting transcriptional dysregulation in cancer. Nat Rev Cancer (2015) 0.87
T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities. Front Immunol (2016) 0.84
Research and development of therapeutic mAbs: An analysis based on pipeline projects. Hum Vaccin Immunother (2015) 0.82
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. J Immunother Cancer (2016) 0.81
Dendritic Cell-Secreted Cytotoxic T-Lymphocyte-Associated Protein-4 Regulates the T-cell Response by Downmodulating Bystander Surface B7. Stem Cells Dev (2016) 0.80
Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors. Viruses (2015) 0.80
Anti-GITR therapy promotes immunity against malignant glioma in a murine model. Cancer Immunol Immunother (2016) 0.78
Kick-starting the cancer-immunity cycle by targeting CD40. Oncoimmunology (2015) 0.78
Tumour and patient factors in renal cell carcinoma-towards personalized therapy. Nat Rev Urol (2015) 0.78
Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model. Cancer Immunol Immunother (2015) 0.78
Combined Immune Therapy for the Treatment of Visceral Leishmaniasis. PLoS Negl Trop Dis (2016) 0.76
Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity. J Transl Med (2016) 0.76
Is immunosenescence influenced by our lifetime "dose" of exercise? Biogerontology (2016) 0.76
Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy. Oncotarget (2016) 0.75
Bridging academic science and clinical research in the search for novel targeted anti-cancer agents. Cancer Biol Med (2015) 0.75
Immune cell interplay in colorectal cancer prognosis. World J Gastrointest Oncol (2015) 0.75
Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials. Transl Oncogenomics (2015) 0.75
Adoptive Immunotherapy for Leukemia with Ex Vivo Expanded T Cells. Curr Drug Targets (2015) 0.75
Intellectual property issues of immune checkpoint inhibitors. MAbs (2015) 0.75
Lymphoepithelioma-like gastric carcinoma located in the lesser curvature of the gastric body: A case report and review of the literature. Mol Clin Oncol (2015) 0.75
Synthetic RORγ agonists regulate multiple pathways to enhance antitumor immunity. Oncoimmunology (2016) 0.75
Immune Checkpoint in Glioblastoma: Promising and Challenging. Front Pharmacol (2017) 0.75
The Implications and Future Perspectives of Nanomedicine for Cancer Stem Cell Targeted Therapies. Front Mol Biosci (2017) 0.75
Targeting Tumor Adaption to Chronic Hypoxia: Implications for Drug Resistance, and How It Can Be Overcome. Int J Mol Sci (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol (2009) 8.68
Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol (2005) 6.18
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A (2003) 5.49
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol (2012) 5.23
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol (2012) 4.44
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol (2013) 3.77
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol (2013) 3.74
Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res (2012) 3.68
Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med (2013) 3.51
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother (2007) 3.32
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer (2010) 3.03
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res (2015) 2.97
Immune modulation in cancer with antibodies. Annu Rev Med (2013) 2.23
Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes--a molecule related to nerve growth factor receptor. EMBO J (1990) 2.21
Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res (1997) 1.94
Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist (2007) 1.93
Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist (2013) 1.91
Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol (2013) 1.65
OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res (2013) 1.57
Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res (2013) 1.39
Mitigating the toxic effects of anticancer immunotherapy. Nat Rev Clin Oncol (2014) 1.23
Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies. Blood (2008) 1.18
Modulation of CTLA-4 and GITR for cancer immunotherapy. Curr Top Microbiol Immunol (2011) 0.80